AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GRAL · NASDAQ · Medical - Diagnostics & Research

GRAIL (GRAL)

Developer of Galleri and targeted methylation tools for cancer detection.

$108.52

vs last close0.00 (0.00%)

GRAIL: Stock Surges As Market Digests FDA Briefing Docs - I Broadly Concur (Rating Upgrade)
Seeking AlphaSep 21
Low False Positives and High Accuracy: FDA Document Fueling Grail Stock Surge
BenzingaSep 21
Grail rallies as FDA staff flags no major concerns for multi-cancer test
ReutersSep 21
Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDA
BarronsSep 21
GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking AlphaSep 14
Concurrent Investment Advisors LLC Grows Position in GRAIL, Inc. $GRAL
Defense WorldSep 9Ownership
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000
The Motley FoolSep 8Ownership
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test
The Motley FoolSep 4Market move
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
MarketBeatAug 14
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL
Defense WorldAug 13
GRAIL: Looking Beyond The NHS-Galleri Headline
Seeking AlphaAug 12
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test
BenzingaAug 10
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GuruFocusAug 7
US FDA to hold advisory meeting to review Grail's multi-cancer test
ReutersAug 7
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
PRNewsWireAug 7
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
Seeking AlphaAug 6
GRAIL Q2 Earnings Call Highlights
MarketBeatAug 5
GRAIL Reports Second Quarter 2026 Financial Results
PRNewsWireAug 5
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL
GlobeNewsWireAug 4
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Business WireAug 4
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile CorpAug 4
GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities Lawsuit - Contact The Gross Law Firm
PRNewsWireAug 4
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
GlobeNewsWireAug 4
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GuruFocusAug 4